

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China Regenerative Medicine International Limited**

**中國再生醫學國際有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8158)**

### **SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION RELATING TO THE SALE OF INTEREST IN A FUND**

Reference is made to the announcement of China Regenerative Medicine International Limited (the “**Company**”) dated 6 January 2020 in relation to a discloseable transaction relating to the sale of interest in a fund (the “**Announcement**”). Terms used herein shall have the same meanings as defined in the Announcement unless otherwise stated.

On 6 January 2020, CRML, a wholly-owned subsidiary of the Company, entered into an agreement to dispose 15% of its Investment in Haitong International ZhongHua Finance Acquisition Fund I, L.P., a sector fund focusing on investments in the skincare and medical products industries (the “**Fund**”), for US\$5,800,000 in cash. The Company plans to use such proceeds generated from the Disposition for general working capital purposes.

The Company would like to provide further information in relation to the proposed use of proceeds:

	<i>HK\$'000</i>
Staff costs	4,500
Rent and rates	17,500
Utilities and other expenses	8,300
Professional fees and corporate expenses	440
Advertising, marketing and promotion expenses	14,500

Furthermore, the board also confirms that it has considered the terms of the Disposition and concluded that they are on normal commercial terms, and are fair and reasonable, and in the interests of the Company and its shareholders as a whole.

Save as disclosed above, all other information and content set out in the Announcement remain unchanged and shall continue to be valid for all purposes. This supplemental announcement is supplemental to and should be read in conjunction with the Announcement.

By Order of the Board  
**China Regenerative Medicine International Limited**  
**Wang Xuejun**  
*Chief Executive Officer and Executive Director*

Hong Kong, 20 January 2020

*As at the date of this announcement, the executive Directors are Mr. Wang Chuang (Chairman) and Mr. Wang Xuejun (Chief Executive Officer); the non-executive Directors are Dr. Ray Yip and Mr. Wu Weiliang; and the independent non-executive Directors are Dr. Fang Jun, Ms. Wang Danjuan and Ms. Yang Ying.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcement” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least seven days from the date of the publication and will be published on the website of the Company at [www.crmi.hk](http://www.crmi.hk).*